Laurus Labs Ltd
P&L
Quarterly Consolidated
vs Q1 FY26
Laurus Labs Announces H1 FY26 Results: Revenues at INR 3,223 Cr, EBITDA at INR 818 Cr, 25.4% Margins
23 Oct 2025 · 23 Oct 2025, 03:29 pm
Summary
Laurus Labs, a leading research and development driven pharmaceutical and biotech company in India, has announced its Q2 & H1 FY26 results. The company reported revenues of INR 3,223 Cr and EBITDA of INR 818 Cr with a margin of 25.4%. The strong H1 performance was driven by the ongoing expansion of the CDMO business and sustained growth in Generics. The company also announced land allocation from the Andhra government and proposed investments to support future business expansion.
Key Highlights
- 1
Revenues at INR 3,223 Cr, representing 33% growth
- 2
EBITDA at INR 818 Cr, representing 132% growth
- 3
EBITDA margins at 25.4%, marking over 10% pts improvement over last year
- 4
Gross margins improved by over 4.5% pts to 59.6%
- 5
Net Debt leverage decreased significantly to 1.3x EBITDA
- 6
Continued investment into manufacturing network expansion and capabilities
- 7
CDMO business reported revenues of INR 1,040 Cr, increased by 74%
- 8
Bio business reported revenues of INR 76 Cr, decreased by 8%
- 9
Generics business reported revenues of INR 2,183 Cr, increased by 20%
- 10
Strong H1 performance with 33% revenues growth
- 11
818 Cr EBITDA with a margin of 25.4%
- 12
Continued investment into manufacturing network expansion and capabilities
- 13
Declared Interim Dividend of INR 0.80/- per share
Management Comments
Dr. Satyanarayana Chava
Founder & Chief Executive Officer
We continue to maintain leadership position in ARVs and make encouraging progress in delivering important clinical and commercial programs. Our Q2 reflects on-going expansion of CDMO business, supported by sustained growth in Generics. We also made strategic investment of US$ 2mn in Aarvik Therapeutics to have access to novel Antibody-drug conjugates (ADC) technology and pipeline aimed at accelerating our integrated ADC services.
V V Ravi Kumar
Executive Director & Chief Financial Officer
Our strong Q2 performance was in line with expectations. We are pleased to report that fundamentals of our business remain strong, with sustained growth momentum in CDMO and Generic business. We have achieved revenues of 1,653 Cr, representing 35% growth and EBITDA of 429 Cr, representing 136% growth. The EBITDA margins continue to remain very healthy at 26.0%, supported by continuing operating leverage.
Informational and educational content only. Not investment advice.